cantharidin has been researched along with Molluscum Contagiosum in 41 studies
Cantharidin: A toxic compound, isolated from the Spanish fly or blistering beetle (Lytta (Cantharis) vesicatoria) and other insects. It is a potent and specific inhibitor of protein phosphatases 1 (PP1) and 2A (PP2A). This compound can produce severe skin inflammation, and is extremely toxic if ingested orally.
cantharidin : A monoterpenoid with an epoxy-bridged cyclic dicarboxylic anhydride structure secreted by many species of blister beetle, and most notably by the Spanish fly, Lytta vesicatoria. Natural toxin inhibitor of protein phosphatases 1 and 2A.
Molluscum Contagiosum: A common, benign, usually self-limited viral infection of the skin and occasionally the conjunctivae by a poxvirus (MOLLUSCUM CONTAGIOSUM VIRUS). (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Compounded cantharidin has been used for decades to treat molluscum contagiosum but lacks rigorous clinical evidence to support its safety and efficacy." | 9.41 | Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum. ( Burnett, P; Davidson, M; Eichenfield, LF; Glover, D; Kwong, P; McBride, M; Olivadoti, M; Rieger, J; Siegfried, E; Willson, C, 2021) |
| "Topical cantharidin is a commonly used treatment for molluscum contagiosum (MC)." | 9.27 | Safety and efficacy of topical cantharidin for the treatment of pediatric molluscum contagiosum: a prospective, randomized, double-blind, placebo-controlled pilot trial. ( Cohen, SR; Garelik, JL; Guzman, AK; Schairer, DO, 2018) |
| "Topical cantharidin demonstrated clearance of warts, particularly in combination with podophyllotixin and salicylic acid, and modest benefit for pediatric molluscum contagiosum with good tolerability and safety." | 8.98 | Efficacy and Safety of Topical Cantharidin Treatment for Molluscum Contagiosum and Warts: A Systematic Review. ( Chopra, R; Silverberg, JI; Silverberg, NB; Vakharia, PP, 2018) |
| "The results contribute to the data supporting cantharidin as a safe and effective treatment of molluscum contagiosum." | 7.75 | Parental satisfaction, efficacy, and adverse events in 54 patients treated with cantharidin for molluscum contagiosum infection. ( Cathcart, S; Coloe, J; Morrell, DS, 2009) |
| "The objective of this study was to assess the efficacy and tolerability of combination therapy for molluscum contagiosum (MC) with topical cantharidin and imiquimod 5%." | 7.72 | Combination topical treatment of molluscum contagiosum with cantharidin and imiquimod 5% in children: a case series of 16 patients. ( Orchard, DC; Ross, GL, 2004) |
| " Safety outcomes included assessment of adverse events, including expected local skin reactions." | 6.94 | Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials. ( Brabec, B; Burnett, P; Davidson, M; Eichenfield, LF; Kwong, P; McBride, M; McFalda, W; Rieger, J; Siegfried, E; Willson, C, 2020) |
| "Compounded cantharidin has been used for decades to treat molluscum contagiosum but lacks rigorous clinical evidence to support its safety and efficacy." | 5.41 | Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum. ( Burnett, P; Davidson, M; Eichenfield, LF; Glover, D; Kwong, P; McBride, M; Olivadoti, M; Rieger, J; Siegfried, E; Willson, C, 2021) |
| "Reasons for actively treating molluscum contagiosum may include alleviation of discomfort and itching (particularly in patients where an eczematous eruption - the so-called "molluscum eczema" - is seen in association) or in patients with ongoing atopic dermatitis where more lesions are likely to be present." | 5.36 | Treatment of molluscum contagiosum with cantharidin: a practical approach. ( Frieden, IJ; Mathes, EF, 2010) |
| "Topical cantharidin demonstrated clearance of warts, particularly in combination with podophyllotixin and salicylic acid, and modest benefit for pediatric molluscum contagiosum with good tolerability and safety." | 4.98 | Efficacy and Safety of Topical Cantharidin Treatment for Molluscum Contagiosum and Warts: A Systematic Review. ( Chopra, R; Silverberg, JI; Silverberg, NB; Vakharia, PP, 2018) |
| "A PubMed search was conducted using the term "cantharidin" combined with "warts", "plantar warts", "verruca vulgaris", "periungal", "subungual", "topical treatment", "topical therapy for warts", molluscum contagiosum", "perforating collagenosis," and "acantholysis." | 4.90 | Cantharidin: a comprehensive review of the clinical literature. ( DeMoll, E; Levitt, J; Pan, M; Torbeck, R, 2014) |
| "The results contribute to the data supporting cantharidin as a safe and effective treatment of molluscum contagiosum." | 3.75 | Parental satisfaction, efficacy, and adverse events in 54 patients treated with cantharidin for molluscum contagiosum infection. ( Cathcart, S; Coloe, J; Morrell, DS, 2009) |
| " Safety outcomes included assessment of adverse events, including expected local skin reactions." | 2.94 | Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials. ( Brabec, B; Burnett, P; Davidson, M; Eichenfield, LF; Kwong, P; McBride, M; McFalda, W; Rieger, J; Siegfried, E; Willson, C, 2020) |
| "Molluscum contagiosum is a viral cutaneous infection in childhood that occurs worldwide." | 2.55 | Molluscum Contagiosum: An Update. ( Barankin, B; Hon, KLE; Leung, AKC, 2017) |
| "Molluscum contagiosum is a viral infection of the skin that is widely considered to be a self-resolving disease that can be treated with benign neglect." | 2.50 | Treatment of molluscum contagiosum in adult, pediatric, and immunodeficient populations. ( Franz, E; Hsu, S; Nguyen, HP; Stiegel, KR; Tyring, SK, 2014) |
| "Warts and molluscum contagiosum are common skin diseases in children and are usually self-limiting." | 2.43 | How and when to treat molluscum contagiosum and warts in children. ( Smolinski, KN; Yan, AC, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (9.76) | 18.7374 |
| 1990's | 1 (2.44) | 18.2507 |
| 2000's | 14 (34.15) | 29.6817 |
| 2010's | 12 (29.27) | 24.3611 |
| 2020's | 10 (24.39) | 2.80 |
| Authors | Studies |
|---|---|
| Eichenfield, L | 1 |
| Hebert, A | 1 |
| Mancini, A | 1 |
| Rosen, T | 1 |
| Weiss, J | 1 |
| Han, H | 1 |
| Smythe, C | 1 |
| Yousefian, F | 1 |
| Berman, B | 1 |
| Gupta, AK | 1 |
| Mann, A | 1 |
| Vincent, K | 1 |
| Abramovits, W | 1 |
| Khattab, FM | 1 |
| Nasr, MM | 1 |
| Ogilvie-Turner, K | 1 |
| Goldman, RD | 1 |
| Eichenfield, LF | 2 |
| McFalda, W | 1 |
| Brabec, B | 2 |
| Siegfried, E | 3 |
| Kwong, P | 2 |
| McBride, M | 2 |
| Rieger, J | 2 |
| Willson, C | 3 |
| Davidson, M | 3 |
| Burnett, P | 3 |
| Zawar, V | 1 |
| Pawar, M | 1 |
| Singh, M | 1 |
| Niazi, S | 1 |
| Anschutz, L | 1 |
| Glover, D | 1 |
| Olivadoti, M | 1 |
| Cotton, CH | 1 |
| Leung, AKC | 1 |
| Barankin, B | 2 |
| Hon, KLE | 1 |
| Forbat, E | 1 |
| Al-Niaimi, F | 1 |
| Ali, FR | 1 |
| Jahnke, MN | 1 |
| Hwang, S | 1 |
| Griffith, JL | 1 |
| Shwayder, T | 1 |
| Guzman, AK | 1 |
| Schairer, DO | 2 |
| Garelik, JL | 1 |
| Cohen, SR | 2 |
| Vakharia, PP | 1 |
| Chopra, R | 1 |
| Silverberg, NB | 4 |
| Silverberg, JI | 1 |
| Storan, ER | 1 |
| Woolf, RT | 1 |
| Smith, CH | 1 |
| Pink, AE | 1 |
| Pompei, DT | 1 |
| Rezzadeh, KS | 1 |
| Viola, KV | 1 |
| Lee, DH | 1 |
| Chismar, LA | 1 |
| Lao, M | 1 |
| Weissler, A | 1 |
| Torbeck, R | 1 |
| Pan, M | 1 |
| DeMoll, E | 1 |
| Levitt, J | 1 |
| Nguyen, HP | 1 |
| Franz, E | 1 |
| Stiegel, KR | 1 |
| Hsu, S | 1 |
| Tyring, SK | 1 |
| Shah, A | 1 |
| Treat, J | 1 |
| Yan, AC | 2 |
| Cathcart, S | 1 |
| Coloe, J | 2 |
| Morrell, DS | 2 |
| Burkhart, CN | 1 |
| Luke, JD | 1 |
| Mathes, EF | 1 |
| Frieden, IJ | 1 |
| Silverberg, N | 1 |
| Langley, JM | 1 |
| Soder, CM | 1 |
| Schlievert, PM | 1 |
| Murray, S | 1 |
| FUNT, TR | 2 |
| Ross, GL | 1 |
| Orchard, DC | 1 |
| Smolinski, KN | 1 |
| Trager, JD | 1 |
| Brown, J | 1 |
| Janniger, CK | 1 |
| Schwartz, RA | 1 |
| Scheinfeld, N | 1 |
| Turchin, I | 1 |
| Lio, P | 1 |
| Rich, JD | 1 |
| Dickinson, BP | 1 |
| Flaxman, AB | 1 |
| Mylonakis, E | 1 |
| Sidbury, R | 1 |
| Mancini, AJ | 1 |
| Epstein, E | 2 |
| Mehr, KA | 1 |
| Lynch, PJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum[NCT03377803] | Phase 3 | 262 participants (Actual) | Interventional | 2018-02-14 | Completed | ||
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum[NCT03377790] | Phase 3 | 266 participants (Actual) | Interventional | 2018-03-21 | Completed | ||
| A Phase 2, Open-Label Study to Evaluate the Safety, Efficacy and Systemic Exposure of VP-102 Topical Film Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum[NCT03186378] | Phase 2 | 33 participants (Actual) | Interventional | 2017-06-08 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change from baseline in the number of treatable molluscum lesions (baseline and new) at the EOS visit. (NCT03377803)
Timeframe: Day 1 (Baseline) compared to Day 84 (EOS)
| Intervention | change in wart count from baseline (Mean) |
|---|---|
| VP-102 | -17.1 |
| Placebo | -10.9 |
Percent change of all treatable molluscum lesions (baseline and new) from baseline at the EOS visit. (NCT03377803)
Timeframe: Day 1 (Baseline) compared to Day 84 (EOS)
| Intervention | percentage change from Baseline (Mean) |
|---|---|
| VP-102 | -83.3 |
| Placebo | -19.1 |
Percentage of subjects exhibiting a 75% or greater reduction of all treatable molluscum lesions (baseline and new) at the EOS visit. (NCT03377803)
Timeframe: Day 1 (Baseline) compared to Day 84(EOS)
| Intervention | Participants (Count of Participants) |
|---|---|
| VP-102 | 122 |
| Placebo | 40 |
Percentage of subjects exhibiting a 90% or greater reduction of all treatable molluscum lesions (baseline and new) at the EOS visit. (NCT03377803)
Timeframe: Day 1 (Baseline) compared to Day 84 (EOS)
| Intervention | Participants (Count of Participants) |
|---|---|
| VP-102 | 105 |
| Placebo | 31 |
Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 21 visit. (NCT03377803)
Timeframe: Day 1 (Baseline) compared to Day 21
| Intervention | Participants (Count of Participants) |
|---|---|
| VP-102 | 8 |
| Placebo | 2 |
Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 42 visit. (NCT03377803)
Timeframe: Day 1 (Baseline) compared to Day 42
| Intervention | Participants (Count of Participants) |
|---|---|
| VP-102 | 19 |
| Placebo | 4 |
Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 63 visit. (NCT03377803)
Timeframe: Day 1 (Baseline) compared to Day 63
| Intervention | Participants (Count of Participants) |
|---|---|
| VP-102 | 42 |
| Placebo | 5 |
Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 84 visit (EOS). (NCT03377803)
Timeframe: Day 1 (Baseline) compared to Day 84 (EOS)
| Intervention | Participants (Count of Participants) |
|---|---|
| VP-102 | 81 |
| Placebo | 15 |
Subject reported spread to household members as measured by any new occurrence of molluscum in household members of subject. (NCT03377803)
Timeframe: Days 1, 21, 42, 63 and 84 (EOS).
| Intervention | Participants (Count of Participants) |
|---|---|
| VP-102 | 10 |
| Placebo | 7 |
"Change from Baseline to EOS Day 84 of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age.~From responses to that questionnaire, a composite score was calculated. The calculated composite score was the sum of the individual 10 items of the CDLQI and could range from 0-30. For each item on the~CDLQI, a score of 0-3 was assigned using the following scores per response:~3: Very much (or Prevented School, Question 7 only)~2: Quite a lot~1: Only a little~0: Not at all Larger composite CDLQI scores indicate skin condition is having more effect on subjects' lives (worse outcome)." (NCT03377803)
Timeframe: Day 1 (Baseline), 21, 42, 63 and Day 84 (EOS)
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Day 21 | Day 42 | Day 63 | Day 84 (EOS) | |
| Placebo | -1.2 | -1.4 | -1.6 | -1.9 |
| VP-102 | -1.0 | -1.5 | -2.0 | -2.1 |
Change from baseline in the number of treatable molluscum lesions (baseline and new) at the EOS visit. (NCT03377790)
Timeframe: Day 1 (Baseline) compared to Day 84 (EOS)
| Intervention | change in wart count (Mean) |
|---|---|
| VP-102 | -18.3 |
| Placebo | -5.9 |
"Change from Baseline to EOS Day 84 of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age.~From responses to that questionnaire, a composite score was calculated. The calculated composite score was the sum of the individual 10 items of the CDLQI and could range from 0-30. For each item on the~CDLQI, a score of 0-3 was assigned using the following scores per response:~3: Very much (or Prevented School, Question 7 only)~2: Quite a lot~1: Only a little~0: Not at all Larger composite CDLQI scores indicate skin condition is having more effect on subjects' lives (worse outcome)." (NCT03377790)
Timeframe: Baseline to Day 84 (EOS)
| Intervention | units on a scale (Mean) |
|---|---|
| VP-102 | -2.1 |
| Placebo | -2.7 |
Percent change of all treatable molluscum lesions (baseline and new) from baseline at the EOS visit. (NCT03377790)
Timeframe: Day 1 (Baseline) compared to Day 84 (EOS)
| Intervention | percentage of change in wart count (Mean) |
|---|---|
| VP-102 | -69.2 |
| Placebo | 20.0 |
Percentage of subjects that exhibited a 75% or greater clearance of all treatable molluscum lesions (baseline and new) at the EOS visit. (NCT03377790)
Timeframe: Day 1 (Baseline) compared to Day 84 (EOS)
| Intervention | Participants (Count of Participants) |
|---|---|
| VP-102 | 119 |
| Placebo | 36 |
Percentage of subjects that exhibited a 90% or greater clearance of all treatable molluscum lesions (baseline and new) at the EOS visit. (NCT03377790)
Timeframe: Day 1 (Baseline) compared to Day 84 (EOS)
| Intervention | Participants (Count of Participants) |
|---|---|
| VP-102 | 99 |
| Placebo | 28 |
Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 42 visit. (NCT03377790)
Timeframe: Day 1 (Baseline and new) compared to Day 42
| Intervention | Participants (Count of Participants) |
|---|---|
| VP-102 | 33 |
| Placebo | 10 |
Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 63 visit. (NCT03377790)
Timeframe: Day 1 (Baseline and new) compared to Day 63
| Intervention | Participants (Count of Participants) |
|---|---|
| VP-102 | 51 |
| Placebo | 18 |
Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 84 visit (EOS). (NCT03377790)
Timeframe: Day 1 (Baseline and new) compared to Day 84 (EOS)
| Intervention | Participants (Count of Participants) |
|---|---|
| VP-102 | 74 |
| Placebo | 19 |
Proportion of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 21 visit. (NCT03377790)
Timeframe: Day 1 (Baseline and new) compared to Day 21
| Intervention | Participants (Count of Participants) |
|---|---|
| VP-102 | 18 |
| Placebo | 4 |
Subject reported spread to household members as measured by any new occurrence of molluscum in household members of subject. To be eligible for assessment, subjects had to have at least one household member free of lesions at baseline and have at least 1 post baseline assessment of spread of molluscum lesions. (NCT03377790)
Timeframe: Days 1, 21, 42, 63 and 84 (EOS).
| Intervention | Participants (Count of Participants) |
|---|---|
| VP-102 | 9 |
| Placebo | 13 |
"Change from Baseline in quality of life and impact of skin disease as measured by CDLQI assessment, Children's Dermatology Life Quality Index (CDLQI)- Composite Score~The CDLQI was a 10-item questionnaire completed by subject/parent to assess skin condition over the previous week. From responses to that questionnaire, a composite score was calculated. The calculated composite score was the sum of the individual 10 items of the CDLQI and could range from 0-30. For each item on the CDLQI, a score of 0-3 was assigned using the following scores per response:~3: Very much (or Prevented School, Question 7 only)~2: Quite a lot~1: Only a little~0: Not at all" (NCT03186378)
Timeframe: Baseline to EOS Day 84
| Intervention | units on a scale change from Baseline (Mean) |
|---|---|
| Exposure Group | 2.71 |
| Standard Group | 2.44 |
Molluscum Lesions- Change from Baseline visit in the number of treated molluscum lesions at the EOS Day 84 visit (NCT03186378)
Timeframe: Baseline to EOS Day 84
| Intervention | change in wart count (Mean) |
|---|---|
| Exposure Group | -39.3 |
| Standard Group | -10.7 |
Percent reduction of treated molluscum lesions from Baseline Visit at the EOS visit. (NCT03186378)
Timeframe: Baseline to EOS Day 84
| Intervention | percentage change from Baseline (Mean) |
|---|---|
| Exposure Group | -87.8 |
| Standard Group | -93.0 |
Spread of molluscum to siblings as measured by any new occurrence of molluscum in siblings of the subject. (NCT03186378)
Timeframe: Baseline to EOS Day 84
| Intervention | Participants (Count of Participants) |
|---|---|
| Exposure Group | 0 |
| Standard Group | 0 |
Proportion of subjects exhibiting complete clearance of all treated molluscum lesions (baseline and new) on or before Week 12 (EOS). (NCT03186378)
Timeframe: Baseline through EOS Day 84
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Complete Clearance Day 21 | Complete Clearance Day 42 | Complete Clearance Day 63 | Complete Clearance EOS Day 84 | |
| Exposure Group | 0 | 2 | 4 | 6 |
| Standard Group | 3 | 7 | 9 | 10 |
Summaries of >=90% clearance by visit include clearance at that visit or any earlier visit (cumulative) baseline and ew at the EOS visit. (NCT03186378)
Timeframe: Baseline to EOS Day 84
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| >=90% Clearance Day 21 | >=90% Clearance Day 42 | >=90% Clearance Day 63 | >=90% Clearance Day 84 | |
| Exposure Group | 0 | 5 | 8 | 12 |
| Standard Group | 3 | 7 | 10 | 13 |
The primary objective is to determine any potential systemic exposure from a single 24-hour dermal application of VP-102 topical film-forming solution when applied to molluscum contagiosum (molluscum) lesions on pediatric subjects 2 years old and older. (NCT03186378)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) Pre-treatment72526484 | Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) 2hr Post Treatment72526484 | Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) 6hr Post Treatment72526484 | Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) 24hr Post Treatment72526484 | |||||
| No | Yes | |||||||
| Exposure Group | 16 | |||||||
| Exposure Group | 1 | |||||||
| Exposure Group | 15 | |||||||
| Exposure Group | 0 | |||||||
12 reviews available for cantharidin and Molluscum Contagiosum
| Article | Year |
|---|---|
Therapeutic Approaches and Special Considerations for Treating Molluscum Contagiosum.
Topics: Adult; Cantharidin; Child; Curettage; Dermatitis, Atopic; Humans; Molluscum Contagiosum; Skin | 2021 |
Molluscum Contagiosum Virus Evasion of Immune Surveillance: A Review.
Topics: Cantharidin; Child; Humans; Molluscum Contagiosum; Molluscum contagiosum virus; Viral Proteins | 2023 |
Molluscum Contagiosum: An Update.
Topics: Age Factors; Cantharidin; Child; Child, Preschool; Cryotherapy; Humans; Irritants; Lasers, Dye; Moll | 2017 |
Molluscum Contagiosum: Review and Update on Management.
Topics: Cantharidin; Cryotherapy; Curettage; Humans; Hydrogen Peroxide; Hydroxides; Lasers, Dye; Molluscum C | 2017 |
Efficacy and Safety of Topical Cantharidin Treatment for Molluscum Contagiosum and Warts: A Systematic Review.
Topics: Administration, Cutaneous; Blister; Cantharidin; Drug Therapy, Combination; Humans; Incidence; Irrit | 2018 |
Cantharidin: a comprehensive review of the clinical literature.
Topics: Administration, Topical; Blister; Cantharidin; Erythema; Humans; Molluscum Contagiosum; Pain; Warts | 2014 |
Treatment of molluscum contagiosum in adult, pediatric, and immunodeficient populations.
Topics: Adjuvants, Immunologic; Adult; Aminoquinolines; Antiviral Agents; Cantharidin; Child; Child, Prescho | 2014 |
Molluscum contagiosum: what's new and true?
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Antipruritics; Cantharidin; Child; Dermatitis, At | 2009 |
Pediatric molluscum contagiosum: optimal treatment strategies.
Topics: Aminoquinolines; Antipruritics; Antiviral Agents; Cantharidin; Child; Child, Preschool; Chronic Dise | 2003 |
How and when to treat molluscum contagiosum and warts in children.
Topics: Adhesives; Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Cantharidin; Child; Cim | 2005 |
Childhood molluscum contagiosum.
Topics: Adjuvants, Immunologic; Adrenal Cortex Hormones; Antiviral Agents; Cantharidin; Child; Cryosurgery; | 2006 |
Warts, molluscum and things that go bump on the skin: a practical guide.
Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Anti-Infective Agents; Cantharidin | 2007 |
7 trials available for cantharidin and Molluscum Contagiosum
| Article | Year |
|---|---|
YCANTH
Topics: Adult; Cantharidin; Child; Double-Blind Method; Drug Combinations; Humans; Molluscum Contagiosum; Tr | 2023 |
A comparative study of topical cantharidin and intralesional PPD to treat molluscum contagiosum.
Topics: Administration, Topical; Adolescent; Adult; Bacterial Proteins; Cantharidin; Child; Child, Preschool | 2020 |
Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.
Topics: Administration, Cutaneous; Adolescent; Cantharidin; Child; Child, Preschool; Double-Blind Method; Dr | 2020 |
Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.
Topics: Administration, Cutaneous; Adolescent; Cantharidin; Child; Child, Preschool; Double-Blind Method; Dr | 2020 |
Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.
Topics: Administration, Cutaneous; Adolescent; Cantharidin; Child; Child, Preschool; Double-Blind Method; Dr | 2020 |
Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.
Topics: Administration, Cutaneous; Adolescent; Cantharidin; Child; Child, Preschool; Double-Blind Method; Dr | 2020 |
A Phase 2 Open-Label Study to Evaluate VP-102 for the Treatment of Molluscum Contagiosum.
Topics: Administration, Cutaneous; Adolescent; Cantharidin; Child; Child, Preschool; Female; Humans; Irritan | 2021 |
Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum.
Topics: Administration, Cutaneous; Adolescent; Cantharidin; Child; Child, Preschool; Double-Blind Method; Eq | 2021 |
Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum.
Topics: Administration, Cutaneous; Adolescent; Cantharidin; Child; Child, Preschool; Double-Blind Method; Eq | 2021 |
Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum.
Topics: Administration, Cutaneous; Adolescent; Cantharidin; Child; Child, Preschool; Double-Blind Method; Eq | 2021 |
Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum.
Topics: Administration, Cutaneous; Adolescent; Cantharidin; Child; Child, Preschool; Double-Blind Method; Eq | 2021 |
Safety and efficacy of topical cantharidin for the treatment of pediatric molluscum contagiosum: a prospective, randomized, double-blind, placebo-controlled pilot trial.
Topics: Cantharidin; Child; Child, Preschool; Double-Blind Method; Female; Humans; Infant; Irritants; Male; | 2018 |
Childhood molluscum contagiosum: experience with cantharidin therapy in 300 patients.
Topics: Blister; Cantharidin; Child; Child, Preschool; Erythema; Female; Humans; Irritants; Male; Molluscum | 2000 |
22 other studies available for cantharidin and Molluscum Contagiosum
| Article | Year |
|---|---|
Cantharidin for molluscum contagiosum.
Topics: Cantharidin; Child; Humans; Molluscum Contagiosum | 2020 |
An Efficacy of Cantharidin Treatment in Facial Molluscum Contagiosum in Younger Children: A Prospective Interventional Study in 67 Children.
Topics: Cantharidin; Child; Humans; Molluscum Contagiosum; Prospective Studies; Treatment Outcome | 2021 |
Pediatric Game Changers∗: Cantharidin for treatment of facial molluscum contagiosum: A retrospective review.
Topics: Cantharidin; Child; Humans; Molluscum Contagiosum; Pain; Retrospective Studies; Treatment Outcome | 2021 |
Cantharidin for treatment of facial molluscum contagiosum: A retrospective review.
Topics: Adolescent; Cantharidin; Child; Child, Preschool; Humans; Infant; Molluscum Contagiosum; Retrospecti | 2018 |
Clearance of molluscum contagiosum virus infection in patients with atopic eczema treated with dupilumab.
Topics: Adult; Antibodies, Monoclonal, Humanized; Cantharidin; Cryotherapy; Dermatitis, Atopic; Drug Resista | 2019 |
Cantharidin therapy: practice patterns and attitudes of health care providers.
Topics: Attitude of Health Personnel; Cantharidin; Enzyme Inhibitors; Health Care Surveys; Humans; Molluscum | 2013 |
Safe and speedy cantharidin application.
Topics: Cantharidin; Dermatology; Humans; Injections, Intralesional; Molluscum Contagiosum; Patient Safety; | 2013 |
Spread of cantharidin after petrolatum use resulting in a varicelliform vesicular dermatitis.
Topics: Cantharidin; Dermatitis, Contact; Enzyme Inhibitors; Female; Humans; Infant; Molluscum Contagiosum; | 2008 |
Parental satisfaction, efficacy, and adverse events in 54 patients treated with cantharidin for molluscum contagiosum infection.
Topics: Adolescent; Cantharidin; Child; Child, Preschool; Cross-Sectional Studies; Enzyme Inhibitors; Female | 2009 |
Vertically transmitted molluscum contagiosum infection.
Topics: Adult; Cantharidin; Dermatologic Agents; Female; Humans; Infant; Infectious Disease Transmission, Ve | 2010 |
Treatment of molluscum contagiosum with cantharidin: a practical approach.
Topics: Cantharidin; Child; Clinical Competence; Enzyme Inhibitors; Humans; Molluscum Contagiosum; Pediatric | 2010 |
Case report: Molluscum contagiosum. Toxic shock syndrome following cantharidin treatment.
Topics: Administration, Topical; Cantharidin; Child, Preschool; Humans; Irritants; Male; Molluscum Contagios | 2003 |
Cantharidin treatment of molluscum contagiosum.
Topics: Cantharidin; Humans; Molluscum Contagiosum | 1961 |
Combination topical treatment of molluscum contagiosum with cantharidin and imiquimod 5% in children: a case series of 16 patients.
Topics: Administration, Topical; Aminoquinolines; Cantharidin; Child; Child, Preschool; Drug Combinations; E | 2004 |
What's your diagnosis? Inflamed vulvar papules in a 7-year-old girl.
Topics: Administration, Topical; Antiviral Agents; Cantharidin; Child; Cryotherapy; Curettage; Diagnosis, Di | 2005 |
Dutasteride, cantharidin, atopiclair, cetuximab, sirolimus, AC-11 and dimericine reviewed in brief.
Topics: Acne Vulgaris; Alopecia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2006 |
Dermacase. Molluscum contagiosum.
Topics: Adjuvants, Immunologic; Aminoquinolines; Cantharidin; Child; Cryotherapy; Curettage; Humans; Imiquim | 2006 |
Local spread of molluscum contagiosum by electrolysis.
Topics: Adult; Cantharidin; Equipment Contamination; Hair Removal; Humans; Irritants; Male; Molluscum Contag | 1999 |
Cantharidin therapy for molluscum contagiosum in children.
Topics: Administration, Topical; Adult; Cantharidin; Child; Humans; Irritants; Molluscum Contagiosum; Occlus | 2001 |
Cantharidin: a valuable office treatment of molluscum contagiosum.
Topics: Cantharidin; Humans; Molluscum Contagiosum | 1979 |
Cantharidin treatment of molluscum contagiosum.
Topics: Cantharidin; Child; Humans; Molluscum Contagiosum | 1989 |
Molluscum contagiosum venereum.
Topics: Cantharidin; Curettage; Epithelial Cells; Female; Humans; Inclusion Bodies, Viral; Molluscum Contagi | 1972 |